(2026). Justification of a medicinal form development based on the api dimethylammonium 3-methyl-2-(2-((e)-styryl)quinazolin-4-ylthio)butanoate with hepatoprotective and antioxidant effects for the needs of military medicine. Ceská a Slovenská farmacie: casopis Ceské farmaceutické spolecnosti a Slovenské farmaceutické spolecnosti, 75(2), E2.
Chicago Style (17th ed.) Citation"Justification of a Medicinal Form Development Based on the Api Dimethylammonium 3-methyl-2-(2-((e)-styryl)quinazolin-4-ylthio)butanoate with Hepatoprotective and Antioxidant Effects for the Needs of Military Medicine." Ceská a Slovenská Farmacie: Casopis Ceské Farmaceutické Spolecnosti a Slovenské Farmaceutické Spolecnosti 75, no. 2 (2026): E2.
MLA (9th ed.) Citation"Justification of a Medicinal Form Development Based on the Api Dimethylammonium 3-methyl-2-(2-((e)-styryl)quinazolin-4-ylthio)butanoate with Hepatoprotective and Antioxidant Effects for the Needs of Military Medicine." Ceská a Slovenská Farmacie: Casopis Ceské Farmaceutické Spolecnosti a Slovenské Farmaceutické Spolecnosti, vol. 75, no. 2, 2026, p. E2.